廣生堂(300436.SZ):GST-HG141獲得II期臨牀試驗研究初步結果短期內不會對公司業績產生重大影響
格隆匯8月14日丨廣生堂(300436.SZ)公佈股票交易異常波動公吿,公司於2024年8月12日披露《關於乙肝治療創新藥GST-HG141獲得II期臨牀試驗研究初步結果且達到預設目標的公吿》。公司關注到部分媒體、股吧、公眾號等平台對相關事項進行轉發、討論,市場關注度較高。GST-HG141臨牀II期研究揭盲結果僅為初步統計分析結果,完整的安全性、藥效學結果將以最終的臨牀總結報吿為準,後續仍需要組織實施好後續臨牀試驗,臨牀研究結果和能否獲批存在不確定性。GST-HG141獲得II期臨牀試驗研究初步結果短期內不會對公司業績產生重大影響,且仍需要持續研發投入
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.